ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. This list will be updated with the posting of errata reports on www.usp.org/USPNF/newOfficialText. This information will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

Page Number	Title	Section	Description
USP34–NF29			
326	⟨788⟩ *Particulate Matter in Injections*	Introduction	Line 16: Change "*Particulate Matter in Injections* ⟨788⟩*Particulate Matter in Injections* ⟨788⟩*Particulate Matter in Injections* ⟨788⟩" to: Parenterals packaged and labeled exclusively for use as irrigating solutions are exempt from the requirements of *Particulate Matter in Injections* ⟨788⟩. Radiopharmaceutical preparations are exempt from the requirements of *Particulate Matter in Injections* ⟨788⟩. Parenteral products for which the labeling specifies the use of a final filter prior to administration are exempt from the requirements of *Particulate Matter in Injections* ⟨788⟩, provided that scientific data are available to justify this exemption.
926	*Indole*	CAS Number	Line 1: Change "*[170-72-9]*" to: *[120-72-9]*
972	*Dibasic Sodium Phosphate TS*	TEST SOLUTIONS	Line 1: Change "Dissolve 12 g of clear crystals of dibasic sodium phosphate in water to make 100 mL." to: Dissolve 12 g of dibasic sodium phosphate in water to make 100 mL.
1071	*Andrographis*	DEFINITION	Line 2: Change "*Andrographis paniculata* Nees." to: *Andrographis paniculata* (Burm. f.) Nees
1146	*Ginger Capsules*	STRENGTH *Content of Gingerols, Gingerdiones, and Shogaols*	Line 6 of *Sample solution*: Change "18 h" to: 16 h
1157	*American Ginseng Capsules*	COMPOSITION	Change "COMPOSITION" to: STRENGTH
1160	*American Ginseng Tablets*	COMPOSITION	Change "COMPOSITION" to: STRENGTH
1226	*St. John's Wort*	*Microbial Enumeration Tests* ⟨61⟩ and *Tests for Specified Microorganisms* ⟨62⟩	Line 3: Change "*Microbial Enumeration Tests* ⟨61⟩ and *Tests for Specified Microorganisms* ⟨62⟩—The total bacterial count does not exceed 10^4 cfu per g, the total combined molds and yeasts count does not exceed 100 cfu per g, and it meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli* and for absence of *Staphylococcus aureus*." to: *Microbial Enumeration Tests* ⟨2021⟩ and *Tests for Specified Microorganisms* ⟨2022⟩—The total bacterial count does not exceed 10^4 cfu per g, the total combined molds and yeasts count does not exceed 10^2 cfu per g, and it meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli* and for absence of *Staphylococcus aureus*.

1232	*Saw Palmetto Capsules*	DEFINITION	Line 2: Change "NLT 22.0% of lauric acid and NMT 34.0% of the labeled amount of Saw Palmetto Extract." to: NLT 22.0% and NMT 34.0% of lauric acid in the labeled amount of Saw Palmetto Extract.
1241	*Turmeric*	*Botanic characteristics*	Line 16 of *Transverse section of rhizome*: Change "15–30 mm" to: 15–30 µm
1242	*Powdered Turmeric*	*Botanic characteristics*	Line 4: Change "15–30 mm" to: 15–30 µm
1249	*Vitamin A Oral Liquid Preparation*	ASSAY *Vitamin A*	Add, after the *Note*, the subsection "*Mobile phase*: *n*-Hexane"
1257	*Oil-Soluble Vitamins Tablets*	*Cholecalciferol or Ergocalciferol (Vitamin D), Method 3*	Line 6 of *Analysis*: Change "Result = $(r_U/r_S) \times (C_S/C_U) \times F \times 100$" to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
			Line 16 of *Analysis*: Delete "F = correction factor to account for the average amount of previtamin D present in the *Sample solution*, 1.09"
1449	*Benzalkonium Chloride Solution*	OTHER COMPONENTS *Alcohol Content (if added)*	*Chromatographic system*, line 1 of *Column*: Change "0.25-mm × 30-cm glass or quartz capillary" to: 0.25-mm × 30-m glass or quartz capillary
1778	*Alcohol*	IMPURITIES *Organic Impurities, Procedure*	Line 1 of *Acetaldehyde and Acetal calculation*: Change "Result = $[(A_E/(A_T - A_E) \times C_S] + [(D_E/(D_T - D_E) \times C_U]$" to: Result = $\{[A_E/(A_T - A_E)] \times C_S\} + \{[D_E/(D_T - D_E)] \times C_U\}$
1903	*Anastrozole*	*Related compounds*	Footnotes 1–5 of *Table 1*: Change "[1] 2-(3-(1-Cyanoethyl)-5-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl)-2-methylpropionitrile [$C_{16}H_{17}N_5$, 279.34]. [2] 2,3-Bis(3-(1-cyano-1-methylethyl)-5-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl)-2-methylpropionitrile [$C_{30}H_{31}N_9$, 517.63]. [3] The relative retention time of anastrozole related compound A has been included for system suitability purposes only and is not intended for quantification. [4] 2,2′-(5-(Bromomethyl)-1,3-phenylene)bis(2-methylpropionitrile) [$C_{15}H_{17}BrN_2$, 305.21]. [5] 2,2′ -(5-(Dibromomethyl)-1,3-phenylene)bis(2-methylpropionitrile) [$C_{15}H_{16}Br_2N_2$, 384.11]." to: [1] 2-(3-(1-Cyanoethyl)-5-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl)-2-methylpropanenitrile [$C_{16}H_{17}N_5$, 279.34]. [2] 2,3-Bis(3-(1-cyano-1-methylethyl)-5-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl)-2-methylpropanenitrile [$C_{30}H_{31}N_9$, 517.63]. [3] The relative retention time of anastrozole related compound A has been included for system suitability purposes only and is not intended for quantification. [4] 2,2′-(5-(Bromomethyl)-1,3-phenylene)bis(2-methylpropanenitrile) [$C_{15}H_{17}BrN_2$, 305.21]. [5] 2,2′ -(5-(Dibromomethyl)-1,3-phenylene)bis(2-methylpropanenitrile) [$C_{15}H_{16}Br_2N_2$, 384.11].
1965	*Azithromycin*	Chemical Information	Line 17: Change "Monohydrate [121479-24-4]" to: Monohydrate [121470-24-4]

2152	*Capsicum*	Definition	Line 1: Change "Capsicum is the dried ripe fruit of *Capsicum frutescens* Linné, known in commerce as African Chillies, or of *Capsicum annuum* Linné var. *connoides* Irish, known in commerce as Tabasco Pepper, or *Capsicum annuum* var. *longum* Sendt, known in commerce as Louisiana Long Pepper; or of a hybrid between the Honka variety of Japanese Capsicum and the Old Louisiana Sport Capsicum known in commerce as Louisiana Sport Pepper (Fam. Solanaceae)." to: Capsicum is the dried ripe fruit of *Capsicum frutescens* L., known in commerce as African chillies or as Tabasco pepper; or of *Capsicum annuum* L. var *connoides* Irish; or of *Capsicum annuum* var. *longum* Sendt, known in commerce as Louisiana Long Pepper, or of a hybrid between the Honka variety of Japanese Capsicum and the Old Louisiana Sport Capsicum known in commerce as Louisiana Sport Pepper (Fam. Solanaceae).
2177	*Carboxymethylcellulose Sodium*	ASSAY *Procedure*	Line 1 of *Analysis*: Change "Titrate the *Sample solution* with 0.1 N perchloric acid VS." to: Titrate the *Sample solution* with 0.1 N perchloric acid VS, determining the endpoint potentiometrically.
2249	*Ceftriaxone Sodium*	Chemical Information	Line 10: Change "sesquaterhydrate" to: hemiseptahydrate
2352	*Citalopram Hydrobromide*	*USP Reference standards* ⟨11⟩	Line 2 of *USP Citalopram Related Compound C RS*: Change "3-(3-*N*,*N*-Dimethylamino)-1-(4-fluorophenyl)-6-cyano-1(3*H*)-isobenzofuranone." to: 3-[3-(Dimethylamino)-1-propyl](4-fluorophenyl)-6-cyano-1(3*H*)-isobenzofuranone.
2354	*Citalopram Tablets*	ADDITIONAL REQUIREMENTS *USP Reference Standards* ⟨11⟩	Line 2 of *USP Citalopram Related Compound C RS*: Change "3-(3-*N*,*N*-Dimethylamino)-1-(4-fluorophenyl)-6-cyano-1(3*H*)-isobenzofuranone." to: 3-[3-(Dimethylamino)-1-propyl](4-fluorophenyl)-6-cyano-1(3*H*)-isobenzofuranone.
2590	*Dimethyl Sulfoxide*	*Related compounds*	Line 4 of *Chromatographic system*: Change "The column temperature is programmed to change from 100° to 170° at a rate of about 10° per minute, the injection port is maintained at a temperature of about 210°, and the detector block is maintained at a temperature of about 220°." to: Initially the column temperature is maintained at 100° for 15 minutes, then is increased at a rate of 10° per minute to a temperature of 170°, and maintained at 170° for 20 minutes. The injection port is maintained at a temperature of about 210°, and the detector block is maintained at a temperature of about 220°.
2924	*Fulvestrant*	*Related compounds*	Line 1, column 2 of the *Table*: Change "Retention Time" to: Relative Retention Time
2986	*Glycerin*	IMPURITIES *Organic Impurities, Procedure 3: Fatty Acids and Esters*	Line 1 of *Sample solution*: Change "Mix 50 g of Glycerin with freshly boiled water" to: Mix 50 g of Glycerin with 50 mL of freshly boiled water
3648	*Nevirapine Tablets*	*Chromatographic purity*	Lines 4–5 of *Procedure*: Change "each impurity/degradation product" to: each unknown impurity/degradation product

3831	*Pectin*	IDENTIFICATION *Procedure*	Line 2 of *Tris buffer solution*: Change "($CaCl_2 \cdot H_2O$)" to: ($CaCl_2 \cdot 2H_2O$)
4083	*Pyrantel Pamoate*	OTHER COMPONENTS *Content of Pamoic Acid*	Delete: "*System suitability* *Sample*: *Standard solution* *Suitability requirements* *Resolution*: NLT 10.0 between pyrantel and pamoic acid *Column efficiency*: NLT 8000 theoretical plates *Tailing factor*: NMT 1.3 for the pyrantel peak *Relative standard deviation*: NMT 1.0% for the pyrantel peak"
4446	*Tioconazole*	ASSAY *Procedure*	Line 2 of *Mobile phase*: Change "add 2.0 mL of ammonium hydroxide." to: add 2.0 mL of ammonium hydroxide to 1120 mL of *Mobile phase*.
4560	*Valrubicin Intravesical Solution*	SPECIFIC TESTS *pH* ⟨791⟩	Line 1: Change "4.0–7.0 in a solution equivalent to 66.7 mg/mL of valrubicin in 0.9% sodium chloride solution" to: *Sample solution*: 1 in 15 solution in 0.9% sodium chloride solution *Acceptance criteria*: 4.0–7.0
4583	*Vinblastine Sulfate*	Chemical Information	Line 1: Change "909.07" to: 909.05
4587	*Vincristine Sulfate for Injection*	PERFORMANCE TESTS *Uniformity of Dosage Units*, *Content Uniformity* ⟨905⟩	Line 5 of *Spectrometric conditions*: Change "*Absorbance*: 262 nm" to: *Analytical wavelength*: 262 nm
Revision Bulletin, Official May 1, 2011			
Online	*Loratadine Oral Solution*	ASSAY *Procedure*	*Chromatographic system*, line 1 under *Column*: Change "4-mm × 30-cm; 10-µm packing L11" to: 3.9-mm × 30-cm; 10-µm packing L11
First Supplement to USP34–NF29			
4654	*Metronidazole Tablets*	IDENTIFICATION	Change "*Sample solution*: 15 mg/mL of metronidazole from powdered Tablets in dilute hydrochloric acid (1:100). Shake for several minutes and filter." to: *Sample stock solution*: 15 mg/mL of metronidazole from powdered Tablets in dilute hydrochloric acid (1:100). Shake for several minutes and filter. *Medium*: Sulfuric acid in methanol (1 in 350) *Sample solution*: 20 µg/mL in *Medium* from *Sample stock solution*

4894	*S-Adenosyl-L-Methionine Disulfate Tosylate*	COMPOSITION *Content of S-Adenosyl-L-Methionine*	Line 19 of *Analysis*: Change "Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ r_U = peak area of *S*-adenosyl-L-methionine from the *Sample solution* r_S = peak area of *S*-adenosyl-L-homocysteine from the *Standard solution* C_S = concentration of *S*-adenosyl-L-homocysteine in the *Standard solution* (mg/mL) C_U = concentration of *S*-adenosyl-L-methionine in the *Sample solution* (mg/mL) M_{r1} = molecular weight of *S*-adenosyl-L-methionine, 399.44 M_{r2} = molecular weight of *S*-adenosyl-L-homocysteine, 384.41 *Acceptance criteria*: 95%–105% on the anhydrous basis" to: Result = $(C/C_U) \times (M_{r1}/M_{r2}) \times 100$ C = concentration of *S*-adenosyl-L-methionine as *S*-adenosyl-L-homocysteine obtained from the linear regression line (mg/mL) C_U = concentration of *S*-Adenosyl-L-Methionine Disulfate Tosylate in the *Sample solution* (mg/mL) M_{r1} = molecular weight of *S*-adenosyl-L-methionine, 399.44 M_{r2} = molecular weight of *S*-adenosyl-L-homocysteine, 384.41 *Acceptance criteria*: 49.5%–54.7% on the anhydrous basis, equivalent to 95.0%–105% of *S*-adenosyl-L-methionine disulfate tosylate on the anhydrous basis
4938	*Citalopram Oral Solution*	IMPURITIES *Organic Impurities, Procedure*	Footnote d of *Impurity Table 1*: Change "3-(3-*N*,*N*-Dimethylamino)-1-(4-fluorophenyl)-6-cyano-1(3*H*)-isobenzofuranone]." to: 3-[3-(Dimethylamino)-1-propyl](4-fluorophenyl)-6-cyano-1(3*H*)-isobenzofuranone.
4949	*Efavirenz*	SPECIFIC TESTS *Enantiomeric Purity*	Line 1 of *Retention time solution*: Change "1 g/mL" to: 1 mg/mL
4965	*Fludarabine Phosphate Injection*	IMPURITIES *Organic Impurities, Procedure 1*	Line 7, column 1 of *Impurity Table 1*: Change "Fludarabine" to: Fludarabine phosphate
		Organic Impurities, Procedure 2	Line 2, column 1 of *Impurity Table 2*: Change "Fludarabine" to: Fludarabine phosphate
5019	*Pramipexole Dihydrochloride*	SPECIFIC TESTS *Enantiomeric Purity*	Line 1 of *Standard solution*: Change "1.5 µg/mL of USP Pramipexole Related Compound D RS in *Mobile phase*" to: 1.5 µg/mL of USP Pramipexole Related Compound D RS in *Mobile phase* from *Standard stock solution*
		ADDITIONAL REQUIREMENTS *USP Reference Standards* ⟨11⟩	Line 1: Change "USP Pramipexole Dihydrochloride RS" to: USP Pramipexole Dihydrochloride RS. [NOTE—Supplied in monohydrate form.]
Second Supplement to USP34–NF29			
5381	*Amoxicillin Capsules*	SPECIFIC TESTS *Microbial Enumeration Tests* ⟨61⟩ and *Tests for Specified Microorganisms* ⟨62⟩	Line 4: Change "10^2 cfu/g" to: 10^2 cfu/g